Stephen Wald, woodcliff Lake, NJ (US); Eduardo J. Martinez, Bryn Mawr, PA (US); Samuel Stratford, Cambridge (GB); Amanda Buist, Cambridge (GB); Joseph Benson, Edinburgh (GB); and Jonathan Loughrey, Edinburgh (GB)
Assigned to Inspirna, Inc., Long Island City, NY (US)
Filed by Inspirna, Inc., Long Island City, NY (US)
Filed on Dec. 7, 2023, as Appl. No. 18/532,133.
Application 18/532,133 is a continuation of application No. 17/821,699, filed on Aug. 23, 2022, granted, now 11,878,956, issued on Jan. 23, 2024.
Application 17/821,699 is a continuation of application No. 17/407,394, filed on Aug. 20, 2021, granted, now 11,459,292, issued on Oct. 4, 2022.
Application 17/407,394 is a continuation of application No. 17/119,527, filed on Dec. 11, 2020, granted, now 11,174,220, issued on Nov. 16, 2021.
Claims priority of provisional application 62/947,968, filed on Dec. 13, 2019.
Prior Publication US 2024/0174595 A1, May 30, 2024
1. A method of cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a zinc salt of 2-[3-[(3R)-3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-(2,2-diphenylethyl)amino]butoxy] phenyl]acetic acid (Compound 1), wherein the zinc salt is a 2:1 (Compound 1:zinc) salt, and wherein the cancer is lung cancer or endometrial cancer.